These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25139691)

  • 1. Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report.
    Sumaili H; Al-Kofide A; Al-Seraihi A; Ayas M; Siddiqui K; El-Solh H; Al-Jefri A; Al-Ahmari A; Mohamed A; Anas M; Belgaumi AF
    Leuk Lymphoma; 2015 May; 56(5):1327-34. PubMed ID: 25139691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Hazar V; Kesik V; Karasu GT; Öztürk G; Küpesiz A; Kılıç SÇ; Ataş E; Uygun V; Eker N; Erbey F; Bengoa ŞY; Emir S; Anak S; Öniz H; Daloğlu H; Aksoylar S; Koçak Ü; Karakükçü M; Elli M; Kurucu N; Yeşilipek A
    Leuk Lymphoma; 2018 Jan; 59(1):85-96. PubMed ID: 28571522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
    Smith SM; van Besien K; Carreras J; Bashey A; Cairo MS; Freytes CO; Gale RP; Hale GA; Hayes-Lattin B; Holmberg LA; Keating A; Maziarz RT; McCarthy PL; Navarro WH; Pavlovsky S; Schouten HC; Seftel M; Wiernik PH; Vose JM; Lazarus HM; Hari P
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):904-12. PubMed ID: 18640574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
    Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
    Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.
    Naik S; Martinez CA; Omer B; Sasa G; Yassine K; Allen CE; Kamdar K; Orth R; Wu M; Leung K; Gottschalk S; Brenner MK; Heslop HE; Krance RA
    Blood Adv; 2019 Sep; 3(18):2689-2695. PubMed ID: 31511228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
    Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
    Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.
    Gross TG; Hale GA; He W; Camitta BM; Sanders JE; Cairo MS; Hayashi RJ; Termuhlen AM; Zhang MJ; Davies SM; Eapen M
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):223-30. PubMed ID: 19800015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
    Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
    Streetly M; Kazmi M; Radia D; Hoyle C; Schey SA
    Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
    Perales MA; Jenq R; Goldberg JD; Wilton AS; Lee SS; Castro-Malaspina HR; Hsu K; Papadopoulos EB; van den Brink MR; Boulad F; Kernan NA; Small TN; Wolden S; Collins NH; Chiu M; Heller G; O'Reilly RJ; Kewalramani T; Young JW; Jakubowski AA
    Bone Marrow Transplant; 2010 Sep; 45(9):1408-16. PubMed ID: 20062091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
    Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G
    Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
    Khattry N; Gupta A; Jain R; Gore A; Thippeswamy R; Jeevangi N; Kannan S; Nair R; Saikia T
    Int J Hematol; 2016 Mar; 103(3):292-8. PubMed ID: 26729297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.